SPARC in Tumor Pathophysiology and as a Potential Therapeutic Target

ISSN: 1873-4286 (Online)
ISSN: 1381-6128 (Print)


Volume 20, 42 Issues, 2014


Download PDF Flyer




Current Pharmaceutical Design

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 62nd of 254 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
William A. Banks
VAPSHCS/GRECC S-182
Building 1, Room 810A
1600 S. Columbian Way
Seattle, WA 98108
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.288
5 - Year: 3.555

SPARC in Tumor Pathophysiology and as a Potential Therapeutic Target

Author(s): Jianguo Feng and Liling Tang

Affiliation: Key Laboratory of Biorheological Sicience and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400044, China.

Abstract

Cell migration and metastasis greatly contribute to the progression of tumors. Secreted Protein and Rich in Cysteine (SPARC), as a multi-faceted protein, is highly expressed in highly metastatic tumors while low or undetectable in less metastatic types with aberrant promoter methylation. In highly metastatic tumors, such as glioblastomas, melanoma, breast cancer and prostate cancer, SPARC promotes bone metastasis and epithelial-mesenchymal transition (EMT). In contrast, this protein acts as an anti-tumor factor in anti-angiogenesis, pro-apoptosis, cell proliferation inhibition and cell cycle arrest in less metastatic tumors, such as neuroblastoma, ovarian cancer, pancreatic cancer, colorectal cancer and gastric cancer. Here, we summarize and analyze the paradoxical role of SPARC in different tumors. We believe that further studies on truncated, alternative splicing variants and signal peptide of SPARC are required to elucidate the distinct effects. Most notably, SPARC variants probably play a crucial role in regulation of transforming growth factor beta (TGF- β) induced EMT. This review also provides strategies to target or use SPARC (full-length, truncated and splicing variants) for therapeutic purposes.

Keywords: Bone metastasis, EMT, highly metastatic tumors, less metastatic tumors, SPARC.

Purchase Online Order Reprints Order Eprints Rights and Permissions

  
  



Article Details

Volume: 20
Issue Number: 39
First Page: 6182
Last Page: 6190
Page Count: 9
DOI: 10.2174/1381612820666140619123255
Advertisement
Advances and Progress in Drug DesignannualSocial

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science